Related references
Note: Only part of the references are listed.Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC
Chao Rong et al.
BRITISH JOURNAL OF CANCER (2020)
Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation
Xiqiao Zhou et al.
CELLULAR ONCOLOGY (2019)
Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy
Madison Canning et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
Hyung Kwon Byeon et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial
Ravindra Uppaluri et al.
CLINICAL CANCER RESEARCH (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins
A. Antignani et al.
ONCOGENE (2017)
Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma
Sufang Yang et al.
ONCOLOGY LETTERS (2017)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer
Annette Affolter et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated
Michal Smida et al.
NATURE COMMUNICATIONS (2016)
c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers
Aijun Shen et al.
CANCER RESEARCH (2015)
RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
T. Rampias et al.
CLINICAL CANCER RESEARCH (2014)
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma
Judy W. King et al.
FUTURE ONCOLOGY (2014)
Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer
Annette Affolter et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2013)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells
Zuqin Nie et al.
CELL (2012)
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
Y. Shao et al.
CELL DEATH AND DIFFERENTIATION (2012)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin et al.
CLINICAL CANCER RESEARCH (2011)
ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE EXTRACELLULAR SIGNAL-RELATED KINASE IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS AFTER IRRADIATION AS PART OF A RESCUE MECHANISM
Annette Affolter et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
The molecular biology of head and neck cancer
C. Rene Leemans et al.
NATURE REVIEWS CANCER (2011)
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma
Jose A. Richter-Larrea et al.
BLOOD (2010)
Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways
Yubin Hao et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo
Xinbin Gu et al.
CLINICAL CANCER RESEARCH (2008)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors
Francesco Marampon et al.
MOLECULAR CANCER (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)